Terms: = Kidney tumors AND EPAS1, MOP2, 2034, ENSG00000116016, PASD2, HIF2A, Q99814
54 results:
1. Boosting Clear Cell Renal Carcinoma-Specific Drug Discovery Using a Deep Learning Algorithm and Single-Cell Analysis.
Wang Y; Chen X; Tang N; Guo M; Ai D
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612943
[TBL] [Abstract] [Full Text] [Related]
2. A novel peptide PDHK1-241aa encoded by circPDHK1 promotes ccRCC progression via interacting with PPP1CA to inhibit AKT dephosphorylation and activate the AKT-mTOR signaling pathway.
Huang B; Ren J; Ma Q; Yang F; Pan X; Zhang Y; Liu Y; Wang C; Zhang D; Wei L; Ran L; Zhao H; Liang C; Wang X; Wang S; Li H; Ning H; Ran A; Li W; Wang Y; Xiao B
Mol Cancer; 2024 Feb; 23(1):34. PubMed ID: 38360682
[TBL] [Abstract] [Full Text] [Related]
3. Genitourinary cancers updates: highlights from ASCO 2023.
Qin Q; Sheffield H; Taasan SM; Wang AZ; Zhang T
J Hematol Oncol; 2023 Nov; 16(1):112. PubMed ID: 37990343
[TBL] [Abstract] [Full Text] [Related]
4. Hypoxia-inducible factor 2α protein and mRNA expression correlate with histomorphological features in clear cell renal cell carcinoma.
Pham T; Ohe C; Yoshida T; Nakamoto T; Kinoshita H; Tsuta K
Pathol Res Pract; 2023 Nov; 251():154841. PubMed ID: 37826874
[TBL] [Abstract] [Full Text] [Related]
5. Selective hif2a Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel-Lindau-Disease-Associated tumors.
Suárez C; Vieito M; Valdivia A; González M; Carles J
Med Sci (Basel); 2023 Jun; 11(3):. PubMed ID: 37489462
[TBL] [Abstract] [Full Text] [Related]
6. Structural basis for binding of the renal carcinoma target hypoxia-inducible factor 2α to prolyl hydroxylase domain 2.
Figg WD; Fiorini G; Chowdhury R; Nakashima Y; Tumber A; McDonough MA; Schofield CJ
Proteins; 2023 Nov; 91(11):1510-1524. PubMed ID: 37449559
[TBL] [Abstract] [Full Text] [Related]
7. [Precision oncology options in urological cancers].
Franz A; Plage H; Fendler A; Schlomm T; Kornienko K
Urologie; 2023 Jul; 62(7):696-704. PubMed ID: 37294331
[TBL] [Abstract] [Full Text] [Related]
8. Comprehensive
Karaghiannis V; Maric D; Garrec C; Maaziz N; Buffet A; Schmitt L; Antunes V; Airaud F; Aral B; Le Roy A; Corbineau S; Mansour-Hendili L; Lesieur V; Rimbert A; Laporte F; Delamare M; Rab M; Bézieau S; Cassinat B; Galacteros F; Gimenez-Roqueplo AP; Burnichon N; Cario H; Van Wijk R; Bento C; Girodon F; Hoogewijs D; Gardie B
Haematologica; 2023 Jun; 108(6):1652-1666. PubMed ID: 36700397
[TBL] [Abstract] [Full Text] [Related]
9. Epigenomic charting and functional annotation of risk loci in renal cell carcinoma.
Nassar AH; Abou Alaiwi S; Baca SC; Adib E; Corona RI; Seo JH; Fonseca MAS; Spisak S; El Zarif T; Tisza V; Braun DA; Du H; He M; Flaifel A; Alchoueiry M; Denize T; Matar SG; Acosta A; Shukla S; Hou Y; Steinharter J; Bouchard G; Berchuck JE; O'Connor E; Bell C; Nuzzo PV; Mary Lee GS; Signoretti S; Hirsch MS; Pomerantz M; Henske E; Gusev A; Lawrenson K; Choueiri TK; Kwiatkowski DJ; Freedman ML
Nat Commun; 2023 Jan; 14(1):346. PubMed ID: 36681680
[TBL] [Abstract] [Full Text] [Related]
10. CD70-Targeted Micelles Enhance HIF2α siRNA Delivery and Inhibit Oncogenic Functions in Patient-Derived Clear Cell Renal Carcinoma Cells.
Trac N; Oh HS; Jones LI; Caliliw R; Ohtake S; Shuch B; Chung EJ
Molecules; 2022 Dec; 27(23):. PubMed ID: 36500549
[TBL] [Abstract] [Full Text] [Related]
11. Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia.
Toledo RA; Jimenez C; Armaiz-Pena G; Arenillas C; Capdevila J; Dahia PLM
Endocr Rev; 2023 Mar; 44(2):312-322. PubMed ID: 36301191
[TBL] [Abstract] [Full Text] [Related]
12. Molecular analysis and favorable clinical outcomes in real-world patients with metastatic renal cell carcinoma.
Donskov F; Pinto CA; Predoiu R; Fox C; Georgsen JB; Skaarup K; Burcu M; Perini R; Steiniche T
Acta Oncol; 2022 Oct; 61(10):1268-1277. PubMed ID: 36112410
[TBL] [Abstract] [Full Text] [Related]
13. Isoform-resolved mRNA profiling of ribosome load defines interplay of HIF and mTOR dysregulation in kidney cancer.
Sugimoto Y; Ratcliffe PJ
Nat Struct Mol Biol; 2022 Sep; 29(9):871-880. PubMed ID: 36097292
[TBL] [Abstract] [Full Text] [Related]
14. Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma.
Tamukong PK; Kuhlmann P; You S; Su S; Wang Y; Yoon S; Gong J; Figlin RA; Janes JL; Freedland SJ; Halabi S; Small EJ; Rini BI; Kim HL
Urol Oncol; 2022 Nov; 40(11):495.e1-495.e10. PubMed ID: 35973929
[TBL] [Abstract] [Full Text] [Related]
15. Organophosphate flame retardant TDCPP: A risk factor for renal cancer?
Zhou X; Zhou X; Yao L; Zhang X; Cong R; Luan J; Zhang T; Song N
Chemosphere; 2022 Oct; 305():135485. PubMed ID: 35764118
[TBL] [Abstract] [Full Text] [Related]
16. The renal lineage factor PAX8 controls oncogenic signalling in kidney cancer.
Patel SA; Hirosue S; Rodrigues P; Vojtasova E; Richardson EK; Ge J; Syafruddin SE; Speed A; Papachristou EK; Baker D; Clarke D; Purvis S; Wesolowski L; Dyas A; Castillon L; Caraffini V; Bihary D; Yong C; Harrison DJ; Stewart GD; Machiela MJ; Purdue MP; Chanock SJ; Warren AY; Samarajiwa SA; Carroll JS; Vanharanta S
Nature; 2022 Jun; 606(7916):999-1006. PubMed ID: 35676472
[TBL] [Abstract] [Full Text] [Related]
17. Immunohistochemical expression of carbonic anhydrase 9, glucose transporter 1, and paired box 8 in von Hippel-Lindau disease-related lesions.
Chatzopoulos K; Aubry MC; Gupta S
Hum Pathol; 2022 May; 123():93-101. PubMed ID: 35196526
[TBL] [Abstract] [Full Text] [Related]
18. PBRM1 Inactivation Promotes Upregulation of Human Endogenous Retroviruses in a HIF-Dependent Manner.
Zhou M; Leung JY; Gessner KH; Hepperla AJ; Simon JM; Davis IJ; Kim WY
Cancer Immunol Res; 2022 Mar; 10(3):285-290. PubMed ID: 35013001
[TBL] [Abstract] [Full Text] [Related]
19. Expression and prognostic significance of EPAS-1 in renal clear cell carcinoma.
Chen B; Wang L; Zhao J; Tan C; Zhao P
Ann Ital Chir; 2021; 92():671-675. PubMed ID: 34807005
[TBL] [Abstract] [Full Text] [Related]
20. A drug repositioning success: The repositioned therapeutic applications and mechanisms of action of thalidomide.
Amare GG; Meharie BG; Belayneh YM
J Oncol Pharm Pract; 2021 Apr; 27(3):673-678. PubMed ID: 33249990
[TBL] [Abstract] [Full Text] [Related]
[Next]
